ArticleBMC medicine2025
Designing novel "Smell-Aids" to improve olfactory function in post COVID-19 era.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05920330 (Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEyeglasses, hearing aids, etc., all serve to enhance the sensory stimuli to enable patients to see or hear things that they would not otherwise be able to, but we have no equivalent technology for olfaction, a pressing issue in the post-COVID era.
methodsWe attempt to invent "Smell-Aids" by non-invasively enhancing intranasal odorant delivery to the olfactory epithelium, using two prototypes: (a) a nasal foam plug with a diagonal channel embedded to direct air/odor flow upwards to the olfactory region; (b) a clip (similar to what synchronized swimmers use) pinching a critical nasal valve region that may intensify the nasal airflow vortex to the olfactory region.
resultsWe first tested these prototypes in counter-balanced orders on 58 healthy subjects, where their measured odor detection thresholds to phenylethyl alcohol significantly improved with both prototypes in subjects with normal smell function (baseline: 8-16.5, n = 30, 12.49 ± 2.8, plug: 14.42 ± 4.9, pinch: 14.73 ± 5.4, p < 0.05), but not in subjects with "super" sensitivity at baseline (> 16.5, n = 28). Next, we tested the prototypes on 54 patients with confirmed olfactory losses (age 21-80 years, median 54.5), the majority of whom (37/54 = 69%) were post-COVID long haulers (infected 12/15/2019 to 10/4/23; persisted 30 to 1260 days, median 22 months). The remaining non-COVID smell losses (n = 17) span significantly longer from 5 months to 27 years (median 8.5 years). The 9-item NIH toolbox odor identification score significantly improved after application of both smell aids (baseline: 4.30 ± 2.27, plug 5.11 ± 2.32, pinch 4.82 ± 2.06, mixed model p < 0.05), especially among the non-COVID cohort. For COVID long haulers, only the nasal plug remained effective (p < 0.05). Subgroup analysis was performed on patients who reported diminished (hyposmia/anosmia 38/54) vs distorted smell (parosmia/phantosmia 27/54, n = 11 reported both) and showed that the nasal plug remains effective for both cohorts (p < 0.05) while the pinch is only effective for the hypo/anosmia cohort (p < 0.05).
conclusionsThese results preliminarily demonstrated the novelty of improving olfactory function through different peripheral mechanisms for different patient and normative cohorts and may one day lead to an effective over-the-counter smell aid. Enhancing olfactory functions in healthy and patient cohorts through improving intranasal air and odorant delivery.
trial registrationClinicalTrials.gov NCT05920330.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.